3L
3L3.F Tactile Systems Technology Inc
- Market cap
- EUR 532M
- P/E
- 26.7x
- P/B
- 2.60x
- ROE
- 7.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 3L3.F undervalued?
Graham number3L3.F trades 75.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tactile Systems Technology Inc fundamental analysis
No fundamental analysis for Tactile Systems Technology Inc yet.
Tactile Systems Technology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tactile Systems Technology Inc
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency…
Full company profileTactile Systems Technology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tactile Systems Technology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 84.5M | 109M | 144M | 189M | 187M | 208M | 247M | 274M | 293M | 330M | 337M |
| Gross Profit | 61.6M | 80.3M | 102M | 134M | 133M | 148M | 176M | 195M | 217M | 250M | 258M |
| Operating Income | 4.27M | 3.90M | 2.99M | 10.5M | -3.63M | -1.76M | -12.8M | 18.0M | 22.2M | 29.3M | 19.8M |
| EBITDA | - | 5.75M | 6.63M | 14.0M | -834K | 1.92M | 1.67M | 26.5M | 32.4M | 39.0M | 29.2M |
| Net Income | 2.88M | 5.86M | 6.62M | 11.0M | -620K | -11.8M | -17.9M | 28.5M | 17.0M | 19.1M | 17.6M |
| EPS | - | 0.33 | 0.36 | 0.57 | -0.03 | -0.59 | -0.88 | 1.21 | 0.71 | 0.85 | 0.78 |
| Balance Sheet | |||||||||||
| Total Assets | 73.9M | 88.4M | 107M | 152M | 174M | 244M | 255M | 281M | 298M | 274M | 291M |
| Total Liabilities | 14.3M | 15.7M | 17.8M | 39.2M | 49.3M | 116M | 134M | 87.8M | 81.3M | 55.0M | 64.0M |
| Shareholders' Equity | 59.6M | 72.8M | 89.3M | 113M | 125M | 128M | 121M | 194M | 217M | 219M | 227M |
| Cash & Short-term Investments | 30.7M | 24.0M | 20.1M | 22.8M | 47.9M | 28.2M | 21.9M | 61.0M | 94.4M | 83.4M | 75.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.03M | 4.19M | 9.01M | 2.51M | 2.79M | 2.63M | 5.21M | 21.4M | 40.7M | 42.8M | 19.9M |
| Capital Expenditure | 833K | 3.75M | 4.20M | 5.45M | 2.06M | 2.10M | 1.78M | 1.62M | 2.51M | 2.54M | 3.67M |
| Free Cash Flow | - | 372K | -539K | -3.48M | 503K | 276K | 3.29M | 19.7M | 38.1M | 40.3M | 16.2M |
| Ratios | |||||||||||
| ROE | 4.8% | 8.0% | 7.4% | 9.7% | -0.5% | -9.2% | -14.7% | 14.7% | 7.8% | 8.7% | 7.7% |
| ROA | 3.9% | 6.6% | 6.2% | 7.2% | -0.4% | -4.8% | -7.0% | 10.1% | 5.7% | 7.0% | 6.0% |
| Net Profit Margin | 3.4% | 5.4% | 4.6% | 5.8% | -0.3% | -5.7% | -7.2% | 10.4% | 5.8% | 5.8% | 5.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tactile Systems Technology Inc dividends
Tactile Systems Technology Inc has not paid dividends in the last 9 fiscal years.
Who owns Tactile Systems Technology Inc
- Insiders 2.23%
- Institutions 97.77%
- Public & others 0.00%
- Shares outstanding 22.4M
- Free float 20.3M
Tactile Systems Technology Inc company profile
- Company name
- Tactile Systems Technology Inc
- Ticker
- 3L3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,086
- Fiscal year end
- December
- Address
- 3701 Wayzata Boulevard, Minneapolis, MN, United States, 55416
- Phone
- 612 355 5100
- Website
- tactilemedical.com
About Tactile Systems Technology Inc
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Tactile Systems Technology Inc management
8- Ms. Sheri Louise DoddCEO, President & Director · born 1966
- Ms. Elaine M. BirkemeyerChief Financial Officer · born 1975
- Ben AmelChief Information Officer
- Ms. Sunday J. Hoy Esq.VP of Regulatory Affairs & Chief Compliance Officer
- Aaron R. SnodgrassSenior Vice President of Sales
- Mr. Nicolaus B. WilsonSenior Vice President of Marketing & Market Access
- Janelle M. StropChief Human Resource Officer
- Dr. Antonios P. Gasparis F.A.C.S., M.D.Chief Medical Officer & Member of Vascular Strategic Advisory Board